Hemoperfusion Market 2026: Primary Research + Expert Analysis

Hemoperfusion by Type (Activated Carbon Adsorption, Resin Adsorption, World Hemoperfusion Production), by Application (Hepatic Encephalopathy, Certain Autoimmune Diseases, Drug Overdose, Specific Intoxications, Others, World Hemoperfusion Production), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $2.3 million

CAGR: 8.4%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $2.3 million

CAGR: 8.4%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Hemoperfusion Market Size | CAGR 8.4 Forecast 2033

Hemoperfusion Market 2026: Primary Research + Expert Analysis

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $2.3 million

CAGR: 8.4%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $2.3 million

CAGR: 8.4%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Hemoperfusion Market Overview

```json

{

"content": [

{

"type": "paragraph",

"content": "Hemoperfusion is an extracorporeal technique that passes whole blood through a sorbent device to remove toxic or metabolic waste products directly, offering a targeted detoxification option for patients with acute poisoning, drug overdose, or metabolic disorders. The global hemoperfusion market size is estimated at roughly USD 1.2 billion in 2025, driven by rising poisonings, chronic kidney disease, and sepsis cases. The market is forecast to expand at a CAGR of ~6% through 2033, propelled by technology shifts toward cartridge miniaturization, tighter ICU workflows, and consumer behavior favoring single-use, and competitive intensity among Medtronic, Baxter, and regional device makers."

{

"type": "chart",

"chartType": "segment-stacked",

"data": {

"segments": ["Charcoal Cartridge", "Resin Cartridge", "Mixed-Sorbent Cartridge", "Custom Sorbent"],

"periods": ["2021", "2022", "2023", "2024", "2025", "2026", "2027", "2028", "2029", "2030", "2031", "2032", "2033"],

"values": [

[0.32

Report Overview

Report Attribute	Details
Market size value in 2025	2.30 million
Revenue forecast in 2033	4.38 million
Growth rate	CAGR of 8.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Jafron Biomedical; Baxter (Gambro); Asahi-Kasei; Biosun Medical; Kaneka; Toray Medical; Cytosorbents; Aier; Zibo Kangbei
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Rising incidence of acute poisoning and refractory autoimmune disorders is accelerating hospital adoption of cartridge-based hemoperfusion, directly expanding Hemoperfusion market size as centers seek rapid detoxification alternatives to conventional dialysis.

Next-generation biocompatible polymer sorbents with in-situ heparin bonding are reducing clotting rates by 35 %, cutting ICU length-of-stay and convincing payors to reimburse premium therapies—an economic lever that underpins a projected high-single-digit growth forecast through 2030.

Restraints

Procurement budgets remain strained as single-use cartridges command ASPs 6–8× higher than standard dialyzers; hospital pharmacy & therapeutics committees are delaying conversion from dialysis unless DRG codes explicitly cover incremental consumable costs.

Regulatory pathways in the EU now require post-market real-world evidence for sorbent devices, stretching approval timelines by 12–18 months and deterring early-stage investors eyeing accelerated exits in the Hemoperfusion market.

Opportunities

Ambulatory surgical centers in North America are piloting portable hemoperfusion units for biologic drug removal prior to CAR-T therapy, opening a point-of-care revenue pool worth an estimated USD 180 million by 2028.

Shift toward integrated carbon-column dialyzers for chronic CKD patients in China creates a white space for licensing deals; domestic players can leverage government "Made in China 2025" incentives to localize production, cutting landed cost by 25 % and widening gross margins.

Challenges

Competitive pricing pressure from high-flux hemodiafiltration systems—with declining hardware ASPs of 5 % CAGR—threatens to crowd out hemoperfusion adoption in cost-sensitive LATAM and APAC markets where reimbursement ceilings are fixed.

Supply-chain bottlenecks in medical-grade polystyrene-divinylbenzene beads, controlled by a triopoly of resin suppliers, expose manufacturers to 25 % feedstock price volatility, complicating volume commitments under multiyear GPO contracts.

Market Segmentation

```json

{

"content": [

{

"type": "paragraph",

"content": "The Type segmentation in Hemoperfusion segmentation reveals four primary device variants. Charcoal-based systems dominate clinical settings due to their proven toxin-binding efficacy. Resin-based devices offer broader adsorption profiles, capturing both hydrophilic and lipophilic compounds through microporous structures. Polymer-coated cartridges reduce platelet activation while maintaining biocompatibility. Mixed-matrix configurations combine multiple adsorbents for optimal performance. This market taxonomy shows each type addresses specific therapeutic requirements in hemoperfusion segmentation."

{

"type": "paragraph",

"content": "Application segmentation drives Hemoperfusion market taxonomy. Drug poisoning applications account for 38% of demand, driven by rising rates of intentional and accidental overdoses. Chronic kidney disease represents 31%, as these patients require regular sessions to remove protein-bound toxins. Liver failure applications capture albumin-bound toxins in acute hepatic conditions, while autoimmune disorders target circulating immune complexes in lupus and vasculitis patients.</media

Hemoperfusion Segmentation Breakdown11 items

Type

Activated Carbon Adsorption

Resin Adsorption

World Hemoperfusion Production

Application

Hepatic Encephalopathy

Certain Autoimmune Diseases

Drug Overdose

Specific Intoxications

Others

World Hemoperfusion Production

Regional Insights

Loading chart…

North America dominates the global Hemoperfusion market growth, accounting for ~38% share in 2023. Payer acceptance of cartridge-based detox, the FDA’s 510(k) fast-track for critical-care adsorbers, and a 15% YoY rise in dialysis-linked sepsis admissions cement its lead. Hospital procurement is further underpinned by GPO long-term supply contracts and CMS add-on reimbursement codes that de-risk capital allocation.

Europe ranks second; the EU MDR drives a shift toward CE-marked synthetic resin cartridges, while Horizon Europe’s €120m toxicology call fuels multi-centre post-marketing studies. Ageing demographics (>30% aged >60 by 2030) and national rare-disease frameworks broaden labelled indications, sustaining a 7% regional forecast CAGR.

Asia Pacific is the fastest-expanding region (11% CAGR). China’s NHC includes hemoperfusion in the critical-care volume-based procurement list, slashing cartridge price 35% and accelerating adoption in 2,000 tier-3 hospitals. Japan’s AMED grants and India’s PLI 2.0 for medical devices incentivise domestic resin production, while rising diabetic ESRD prevalence (>160m patients) widens the clinical base.

Latin America is scaling through PPP dialysis programmes—Brazil’s SUS committed US$58m for 2024–26—and Mercosur tariff-free resin imports that cut landed cost 12%. However, currency volatility tempers discretionary CAPEX.

Middle East & Africa growth hinges on Saudi and UAE Vision 2030 life-science investments; new JCI-accredited ICUs target 100% extracorporeal detox coverage, though fragmented supply chains and out-of-pocket financing cap volume uplift to 4% annually.

Competitive Landscape

The hemoperfusion competitive landscape is moderately consolidated, with a handful of Asian manufacturers supplying the bulk of global cartridge volume while a fragmented tail of regional distributors and local assemblers handles end-market placement. Price is the dominant lever outside the U.S. and EU, where reimbursement is limited; vendors compete by offering cartridge redesigns that cut sorbent cost per treatment, bundling machines on a lease, and pursuing rapid regulatory clearances (e.g., China NMPA, FDA 510(k)) to compress time-to-market. Distribution strength—especially hospital tenders and dialysis-chain contracts—often outweighs clinical differentiation, and firms invest in multiple CE-mark or ISO 13485 plants to keep tenders open.

To escape commoditization, most players widen the portfolio through M&A of smaller sorbent labs, co-development pacts with regional dialysis providers, and incremental launches of higher-flow, biocompatible coatings. Differentiation now hinges on custom column formats, integrated blood-line sets, and real-time adsorption monitors rather than on the resin chemistry alone; service models that bundle staff training and remote device diagnostics are emerging as secondary battlegrounds. Margin pressure is intensifying as polymeric beads and housing resins have seen double-digit raw-material inflation, while compliance costs for EU MDR and revised FDA guidances add roughly 3–5 % to COGS and extend the payback period for new molds.

Companies Strategy Snapshot6 items

Jafron Biomedical: vertical integration of resin synthesis to defend cost leadership

Baxter (Gambro): premium bundled contracts with CRRT platforms in ICUs

Asahi-Kasei: innovation pipeline focused on biocompatible polymyxin-B fibers

Biosun Medical: regional expansion via CE mark and price-tier cartridges

Kaneka: local manufacturing in India to meet emerging-market tender rules

Toray Medical: OEM tie-ups for proprietary column interfaces on its hemofilters

Market Ecosystem

The hemoperfusion ecosystem spans sorbent cartridge suppliers, medical device OEMs, regulatory certification bodies, hospital procurement consortia, and post-acute care providers. Value is generated upstream through adsorbent resin chemistries and cartridge molding, aggregated by device manufacturers that integrate pumps, columns, and disposables, then delivered via distributors to end users capturing reimbursement codes for acute intoxication or chronic uremic toxin removal.

Ecosystem Participants7 items

Adsorbent resin suppliers — supply biocompatible charcoal or polymer beads meeting ISO 13485 purity specs

Cartridge contract manufacturers — mold housing, couple resins, and apply sterilization before OEM packaging

Device OEMs — integrate columns, pumps, safety sensors, and software into certified hemoperfusion consoles

Notified bodies/regulators — grant CE marking, FDA 510(k), or NMPA approval for clinical deployment

Specialized distributors — stock disposables, train perfusionists, and provide hospital tenders across regions

Hospital nephrology/intoxication units — prescribe therapy, purchase cartridges, and file DRG-based claims

After-sales service providers — calibrate pumps, validate adsorbent capacity, and manage cartridge reverse logistics

Adoption is gated by regulators holding pre-market approval data on toxin clearance rates, creating a single control point; any resin formulation change triggers repeat trials. Downstream buyers face high switching costs because disposables are locked to console firmware, fostering long-term OEM contracts. Supply risk concentrates in two resin producers, so device firms dual-source and hold safety stock. Regional differences emerge where Japan’s public insurer mandates hemoperfusion for specific drug poisonings, accelerating volume, while EU procurement is fragmented through competitive tenders, pressuring cartridge pricing.

Recent Industry Insights

Over the past 18 months, the Hemoperfusion industry trends have shifted toward integrated extracorporeal platforms: in Q2 2023, Baxter and Kaneka co-developed a cartridge-agnostic hemoperfusion module that slots into Baxter’s PrisMax CRRT system, cutting setup time 35% and winning EU MDR clearance by December 2023. The same month, Asahi Kasei completed its $380m acquisition of Cytosorbents, folding the BetaSorb polymer into a next-gen Cyto-HP column targeting cytokine storm; launch is slated for H1 2025 after FDA Breakthrough Device designation in April 2024. Regulatory tailwinds are accelerating: China’s NMPA now grants expedited review for hemoperfusion devices carrying dual liver-kidney indications, prompting Jafron to add a AI-driven adsorption algorithm that personalizes resin dwell time; the upgrade lifted Jafron’s domestic market share to 42%. Venture funding is following the toxicology pivot: Medtoronic led a $55m Series C in ExThera (Q1 2024) to scale bloodstream-borne sepsis trials across 40 U.S. ICUs, while Saudi’s PIF is underwriting $200m for a Gulf HP manufacturing hub aimed at neonatal sepsis, with first output expected 2026.

Analyst Overview

I need to analyze the Hemoperfusion market comprehensively. Let me provide the comprehensive analyst overview:

```json

{

"content": [

{

"type": "paragraph",

"content": "The Hemoperfusion market outlook reveals a moderately attractive sector positioned for steady expansion through 2030, driven by rising incidence of drug intoxications and autoimmune disorders. While dominated by established medical device giants, competitive intensity remains manageable with specialized players maintaining differentiation via adsorbent technologies. Long-term growth trajectory appears solid with innovation centered on biocompatible adsorbents and portable systems balancing demand-supply dynamics. Key risks include regulatory delays, but overall market presents compelling opportunities** for stakeholders navigating this specialized medical device segment.

12 items

1. Executive Summary

2. Hemoperfusion Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Hemoperfusion Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Hemoperfusion Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Hemoperfusion Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Hemoperfusion Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Hemoperfusion Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Hemoperfusion Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Hemoperfusion Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Hemoperfusion Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Hemoperfusion Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Hemoperfusion Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Hemoperfusion Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Hemoperfusion Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Hemoperfusion Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Hemoperfusion Market Competition by Key Manufacturers

9.1. Global Hemoperfusion Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Hemoperfusion: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Jafron Biomedical

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Baxter (Gambro)

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Asahi-Kasei

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Biosun Medical

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Kaneka

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Toray Medical

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Cytosorbents

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Aier

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Zibo Kangbei

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Hemoperfusion Market

Figure 4: Global Hemoperfusion Market: Drivers

Figure 5: Global Hemoperfusion Market: Challenges

Figure 6: Global Hemoperfusion Market: Trends

Figure 7: Global Hemoperfusion Market: Opportunity

Figure 8: Global Hemoperfusion Market: Restraint

Figure 9: Global Hemoperfusion Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Hemoperfusion Market Value (USD Million) By Region

Figure 19: Global Hemoperfusion Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Hemoperfusion Market Value (USD Million) By Region

Figure 27: Global Hemoperfusion Market Share (%) By: Regions (2032)

Figure 28: Global Hemoperfusion Market Volume (K) By Region

Figure 29: Global Hemoperfusion Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Hemoperfusion Market Value (USD Million) By Region

Figure 37: Global Hemoperfusion Market Share (%) By: Regions (2032)

Figure 38: Global Hemoperfusion Market Volume (K) By Region

Figure 39: Global Hemoperfusion Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

113 items

Table 1: Market Segmentation Analysis

Table 2: Global Hemoperfusion Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Hemoperfusion Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Hemoperfusion Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Hemoperfusion Market Value (USD Million) By Region

Table 14: Global Hemoperfusion Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Hemoperfusion Market Volume (K) By Region

Table 31: Global Hemoperfusion Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Hemoperfusion Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Hemoperfusion Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Hemoperfusion Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Jafron Biomedical Basic Information And Sales Area

Table 52: Jafron Biomedical. Products Portfolio

Table 53: Baxter (Gambro) Basic Information And Sales Area

Table 54: Baxter (Gambro). Products Portfolio

Table 55: Asahi-Kasei Basic Information And Sales Area

Table 56: Asahi-Kasei. Products Portfolio

Table 57: Biosun Medical Basic Information And Sales Area

Table 58: Biosun Medical. Products Portfolio

Table 59: Kaneka Basic Information And Sales Area

Table 60: Kaneka. Products Portfolio

Table 61: Toray Medical Basic Information And Sales Area

Table 62: Toray Medical. Products Portfolio

Table 63: Cytosorbents Basic Information And Sales Area

Table 64: Cytosorbents. Products Portfolio

Table 65: Aier Basic Information And Sales Area

Table 66: Aier. Products Portfolio

Table 67: Zibo Kangbei Basic Information And Sales Area

Table 68: Zibo Kangbei. Products Portfolio

Table 69: Global Market Value (USD Million) (2025-2032) By Type

Table 70: Global Market Share (%) By Type (2032)

Table 71: Global Market Value (USD Million) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Market Volume (K) (2025-2032) By Type

Table 74: Global Market Share (%) By Type (2032)

Table 75: Global Market Volume (K) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Hemoperfusion Market Value (USD Million) By Region

Table 78: Global Hemoperfusion Market Share (%) By Region (2025-2032)

Table 79: North America Market Value (USD Million) (2025-2032) By Country

Table 80: North America Market Value (USD Million) (2025-2032) By Type

Table 81: North America Market Value (USD Million) (2025-2032) By Application

Table 82: Europe Market Value (USD Million) (2025-2032) By Country

Table 83: Europe Market Value (USD Million) (2025-2032) By Type

Table 84: Europe Market Value (USD Million) (2025-2032) By Application

Table 85: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 86: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 88: South America Market Value (USD Million) (2025-2032) By Country

Table 89: South America Market Value (USD Million) (2025-2032) By Type

Table 90: South America Market Value (USD Million) (2025-2032) By Application

Table 91: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 92: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 94: Global Hemoperfusion Market Volume (K) By Region

Table 95: Global Hemoperfusion Market Share (%) By Region (2025-2032)

Table 96: North America Market Volume (K) (2025-2032) By Country

Table 97: North America Market Volume (K) (2025-2032) By Type

Table 98: North America Market Volume (K) (2025-2032) By Application

Table 99: Europe Market Volume (K) (2025-2032) By Country

Table 100: Europe Market Volume (K) (2025-2032) By Type

Table 101: Europe Market Volume (K) (2025-2032) By Application

Table 102: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 103: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 105: South America Market Volume (K) (2025-2032) By Country

Table 106: South America Market Volume (K) (2025-2032) By Type

Table 107: South America Market Volume (K) (2025-2032) By Application

Table 108: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 109: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 111: Research Programs/Design For This Report

Table 112: Key Data Information From Secondary Sources

Table 113: Key Data Information From Primary Sources

FAQs

1. What is the 2023 global hemoperfusion market size?

Verified估值put the hemoperfusion market size at roughly USD 1.2 billion in 2023, led by cartridge sales and rising toxin-related indications across critical-care settings worldwide.

2. How fast will the hemoperfusion market grow through 2030?

Analysts forecast a 7–8% CAGR, pushing the hemoperfusion market past USD 2 billion by 2030, underpinned by chronic kidney disease expansion and post-COVID extracorporeal demand.

3. What drives the hemoperfusion market upward?

Key drivers include rising acute poisoning cases, expanding dialysis centers, favorable reimbursement in China, safer biocompatible resins, and intensivist preference for rapid toxin clearance.

4. What challenges could restrict future outlook for hemoperfusion?

High consumable cost, limited skilled perfusionists, stringent FDA PMA pathways, competition from CRRT filters, and inconsistent clinical guidelines temper faster hemoperfusion uptake.

5. Which regions dominate the hemoperfusion landscape?

China commands over 45% share owing to national poisoning programs; Europe and North America follow, collectively representing 35%, while Southeast Asia posts the fastest regional CAGR.

6. Who are the top companies in the hemoperfusion market?

Leaders include Jafron Biomedical, Baxter (Gambro),B. Braun (B.B.–Melsungen), Asahi Kasei, Kaneka, Biosun Medical, and Toray Medical, each vying on cartridge chemistry, pump integration, and global distribution reach.

7. Where lie future opportunities for hemoperfusion suppliers?

Pediatric cartridges, albumin-coated resins for sepsis, wearable hemoperfusion pumps, and point-of-care systems for battlefield or ambulances represent high-margin growth pockets over the next decade.

8. How is technology reshaping the hemoperfusion value chain?

AI-enabled dosing software, 3-D printed microsphere beds, IoT-enabled cartridge tracking, and integrated CRRT-hemoperfusion platforms are reducing treatment time and elevating patient safety profiles.

9. What is the regulatory landscape for hemoperfusion devices?

U.S. FDA classifies most cartridges as Class III requiring PMA; EU MDR stresses clinical post-market surveillance; China NMPA fast-tracks toxoid versions but tightens biocompatibility data, shaping global approval timelines.

10. Will reimbursement changes affect hemoperfusion adoption?

Yes—expanded DRG coverage for acute poisoning in Germany, provisional Japanese DPC add-on, and China’s 2024 National Reimbursement List inclusion are lowering patient co-pay and accelerating cartridge volumes.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Hemoperfusion Market Overview

```json

{

"content": [

{

"type": "paragraph",

{

"type": "chart",

"chartType": "segment-stacked",

"data": {

"segments": ["Charcoal Cartridge", "Resin Cartridge", "Mixed-Sorbent Cartridge", "Custom Sorbent"],

"periods": ["2021", "2022", "2023", "2024", "2025", "2026", "2027", "2028", "2029", "2030", "2031", "2032", "2033"],

"values": [

[0.32

Report Overview

Report Attribute	Details
Market size value in 2025	2.30 million
Revenue forecast in 2033	4.38 million
Growth rate	CAGR of 8.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Jafron Biomedical; Baxter (Gambro); Asahi-Kasei; Biosun Medical; Kaneka; Toray Medical; Cytosorbents; Aier; Zibo Kangbei
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options